Nicorandil-Induced Colovesical Fistula in a Patient with Diverticular Disease by Noyes, James D. et al.
                                                                    
University of Dundee
Nicorandil-Induced Colovesical Fistula in a Patient with Diverticular Disease








Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Noyes, J. D., Mordi, I. R., Zeb, Q., & Lang, C. C. (2021). Nicorandil-Induced Colovesical Fistula in a Patient with
Diverticular Disease. Clinical Case Reports, 9(3), 1737-1741. https://doi.org/10.1002/ccr3.3888
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 20. Apr. 2021
Clin Case Rep. 2021;00:1–5.    | 1wileyonlinelibrary.com/journal/ccr3
Received: 30 September 2020 | Revised: 21 January 2021 | Accepted: 22 January 2021
DOI: 10.1002/ccr3.3888  
C A S E  R E P O R T
Nicorandil- induced colovesical fistula in a patient with 
diverticular disease
James D. Noyes  |   Ify R. Mordi |   Qaiser Zeb |   Chim C. Lang
Division of Molecular & Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Correspondence
Chim C. Lang, Division of Molecular & 
Clinical Medicine, School of Medicine, 






Nicorandil's adverse effects can cause severe patient morbidity and can present 
to any specialty. Those with underlying diverticular disease are most susceptible. 
Medication reviews are vital for patients presenting with ulcer or fistula symptoms.
1 |  INTRODUCTION
Nicorandil, a commonly prescribed antianginal drug, has 
been linked to the development of gastrointestinal ulcers and 
fistulas. Its use is cautioned in diverticular disease; however, 
this is not apparent to many prescribers. Early identification 
of nicorandil's adverse drug effects coupled with prompt ces-
sation of treatment can prevent significant patient harm.
The most recent figures show that there are 2.3 million 
people in the United Kingdom living with coronary heart dis-
ease.1 Nicorandil is recommended by the European Society 
of Cardiology for the treatment of chronic coronary syn-
dromes as a second line therapy after beta blockers, calcium 
channel blockers, and long acting nitrates.2 It acts to dilate 
coronary resistance arterioles through the activation of ade-
nosine triphosphate sensitive potassium channels and dilates 
both epicardial coronary arteries alongside systemic veins 
through nitric oxide donation. These actions result in in-
creased coronary blood flow with a reduction of both preload 
and afterload.3 The off- target side effects of this therapy can 
have major consequences to patients, especially those with 
diverticular disease.
The term “diverticular disease” incorporates both the pres-
ence of diverticula and diverticulitis. The majority of people 
aged 60 and over in Western populations have diverticular 
disease which is often asymptomatic. Therefore, the potential 
for nicorandil to cause widespread harm to patients is high.4 
Recognizing patients who are experiencing nicorandil's side 
effects cannot be limited to one speciality. The adverse ef-
fects can be wide ranging and ulcers can occur at any skin or 
mucosal site; including the eyes and oral cavity.5 Therefore, 
it is important to widely educate healthcare professionals 
to identify these signs so that nicorandil can be promptly 
stopped and alternatives offered by a cardiologist. In addition 
to reducing significant patient burden, cardiovascular thera-
pies are major contributors to the NHS’ annual £466 million 
bill from adverse drug reaction related hospital admissions.6
This case report follows a 61- year- old gentleman who was 
prescribed nicorandil for his stable angina in the background 
of CT- proven diverticular disease. Two years after initiation 
of nicorandil he developed a colovesical fistula which re-
sulted in numerous hospital admissions and major surgery. 
He remained on nicorandil for seven years post fistula diag-
nosis. Through highlighting this case, we aim to reduce fu-
ture patient morbidity caused by nicorandil's adverse effects.
2 |  CASE HISTORY
The patient was first prescribed nicorandil in 2010 to treat re-
current episodes of chest pain, resistant to first- line therapies, 
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which were not associated with elevated troponin levels 
or abnormalities on coronary angiography. His past medi-
cal history included two myocardial infarctions. In 2012, 
the patient presented to his general practitioner (GP) with a 
five- day history of increased urinary frequency and a clear 
discharge after micturition. Urinalysis revealed leucocytes, 
nitrites, blood, and protein. He was commenced empirically 
on a seven- day course of trimethoprim; urine culture results 
showed a mixed growth of organisms. His symptoms did not 
improve with antibiotic therapy and he quickly represented 
to his GP. Further questioning at this time revealed he was 
passing air at the end of micturition for up to 10  seconds. 
Additionally, he reported the presence of “tissue” in his urine 
which was dark in color. There were no reports of frank he-
maturia or fever. On examination, vital signs were normal, 
and abdominal examination revealed suprapubic tenderness 
radiating to his left iliac fossa. An urgent follow- up by the 
colorectal team was requested.
3 |  INVESTIGATIONS
The colorectal team carried out a CT scan of his abdomen 
and pelvis, colonoscopy, and barium enema. The CT scan 
showed a channel of communication from the mid- rectum 
into the posterior bladder. Gas locules were visualized in the 
urinary bladder alongside a trace of rectal contrast. Barium 
enema showed a leakage of barium from the rectum anteri-
orly passing anteriorly to fill an irregular cavity (Figure 1). 
Colonoscopy findings excluded any malignant disease.
The CT scan was compared with a previous abdominal 
CT scan carried out three years earlier, undertaken due to an 
acute episode of abdominal pain which was attributed to a 
paracolic abscess around an area of diverticular disease of the 
sigmoid colon. The updated CT scan showed that the identi-
fied communication was a new finding and the previously ob-
served paracolic abscess had completely resolved. Due to the 
location of the fistula, a defunctioning ileostomy was offered 
to the patient which he declined at the time due to his anxiety 
about having surgery.
In 2017, he re- presented with urosepsis and a further ab-
dominal CT scan showed an additional fistula had formed. 
The second colovesical fistula was located between a diver-
ticulum and the anterior superior bladder; the previously 
identified fistula, located at the posterior bladder, was still 
patent.
4 |  DIFFERENTIAL DIAGNOSIS
The clinical presentation and examination findings strongly 
suggested that the patient had an abnormal connection be-
tween his colon and bladder. Investigations were essential 
for two reasons: firstly, to understand the anatomy of this 
suspected abnormal connection and secondly to establish its 
cause.
A number of different pathologies can result in colove-
sical fistula formation. The most important to exclude was 
malignancy. The clinical history was not suggestive of this 
as the patient reported no change in bowel habits, weight loss 
or family history of malignancy. However, colonoscopy was 
essential to definitively exclude this. Findings from this ex-
amination were also able to eliminate inflammatory bowel 
disease as an underlying cause of his fistula.
The CT scan findings showed significant diverticular 
disease of the sigmoid colon, which in the absence of other 
pathology appeared the most likely cause of the fistula. The 
potential role that nicorandil played in this process was not 
initially considered.
5 |  TREATMENT
To prevent further episodes of urosepsis, surgical treatment 
was required to remove the diseased colon containing diver-
ticula. The patient underwent an elective Hartmann's pro-
cedure with end colostomy in 2018. Intraoperative findings 
revealed the sigmoid colon was adhered to the posterior as-
pect of the bladder. The sigmoid colon was dissected from 
the bladder and removed, leaving a healthy rectal stump in 
situ.
Postoperatively, blood was observed in his catheter bag 
and urine was noted to be leaking from the patient's rectal 
stump. This was investigated with a cystogram which showed 
evidence of contrast leaking from the posterior bladder into 
F I G U R E  1  Barium enema highlighting the fistula between the 
rectum and bladder
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bowel (Figure 2). A repeat CT scan revealed a persistent fis-
tula located in the posterior bladder connecting to the defunc-
tioned rectal stump. The patient received a further course of 
antibiotics to treat a proven urinary tract infection prior to 
his hospital discharge. He represented two weeks later with a 
wound infection and wound dehiscence, requiring emergency 
surgical intervention. At this time a urological opinion was 
sought and consideration was given to long- term catheter use.
6 |  OUTCOME AND FOLLOW- UP
Subsequent clinic review by the colorectal team found that he 
was still symptomatic, suggesting the fistula was not healing 
despite catheter use. His symptoms were most severe when 
the catheter became blocked. In light of this, the decision was 
taken to make the catheter permanent and to have regular 
catheter changes scheduled in the community. The psycho-
logical burden of his ongoing symptoms had a large negative 
impact on his quality of life and there were periods of time 
when the patient felt unable to leave his home.
Shortly after the Hartmann's procedure, he was routinely 
reviewed by the cardiology team. At this time the association 
between the patient's fistula and nicorandil use was noted, 
seven years after the fistula was first diagnosed. The cardi-
ology team stopped the nicorandil and started the patient on 
an alternative antianginal therapy, ranolazine. The patient's 
anginal symptoms have since been well controlled on this 
new therapy.
No further interventions regarding his fistula are currently 
planned as he has recently received a new diagnosis, unre-
lated to the above history, of a squamous cell carcinoma with 
extensive cervical nodal metastases.
7 |  DISCUSSION
This case demonstrates the significant morbidity that diver-
ticular disease can cause patients when complications de-
velop. While fistula formation is a known consequence of 
diverticular disease in the absence of nicorandil, evidence 
shows that patients with diverticular disease on nicorandil 
therapy have a 7- fold increased risk of fistula formation com-
pared to those not taking the drug.7 Previous case series have 
also highlighted nicorandil's link to fistulation between or-
gans.8 Despite published evidence and the British National 
Formulary's caution, this case shows that nicorandil continues 
to be prescribed to at- risk patients. The case also illustrates 
the challenge of promptly identifying nicorandil's adverse ef-
fects as patients rarely present back to cardiology with their 
symptoms. It is far more common for patients to seek help 
from others, such as general practitioners, dermatologists or 
surgeons who may be less familiar with nicorandil.9
The pathophysiology of nicorandil- induced ulceration 
and fistulation is yet to be determined. The most probable 
mechanism involves the accumulation of nicorandil's metab-
olites, nicotinic acid, and nicotinamide. In normal circum-
stance, these combine to form a pool of nicotinamide adenine 
dinucleotide which is found widely in organisms and causes 
no harm. In certain people who suffer from adverse effects, it 
is postulated that this pool becomes saturated leading to the 
accumulation of the individual toxic metabolites.
Nicotinamide then increases blood flow at the edge of 
a vulnerable area which stimulates epithelial proliferation. 
Nicotinic acid subsequently ulcerates this epithelial layer 
and floods the remaining vulnerable tissue.10 In the colon, 
diverticula are formed at points of blood vessel herniation 
through the muscle wall creating vulnerable tissue with a 
rich vascular supply. Nicorandil- induced fistulation has also 
been hypothesized to occur as a result of the release of pro- 
inflammatory nitric oxide in the sigmoid mucosa.7
Local prescribing guidance for stable angina, based on 
Scottish Intercollegiate Network Guideline (SIGN) 96 and 
National Institute for Health and Care Excellence (NICE) 
Clinical Guideline 126, recommends adding nicorandil after 
a beta blocker or/and a calcium channel blocker and isosor-
bide mononitrate. Within our health board, nicorandil can be 
started by primary care doctors without cardiology consulta-
tion. The local protocol specifically states nicorandil should 
“not be used in patients with prior or risk factors for gastroin-
testinal ulceration.”11 Further treatments, such as ranolazine, 
can only be prescribed with permission of a consultant car-
diologist in our region with initial prescriptions coming from 
the main hospital pharmacy. Prior to this, requests had to be 
granted through individual patient treatment requests to the 
Scottish Medicines Consortium.
A 10- year observational study of French nicorandil- 
induced ulceration cases concluded that their development 
F I G U R E  2  Cystogram highlighting the leakage of contrast from 
the bladder into the bowel
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could not be predicted.10 Evidence has been discussed show-
ing that individuals with known diverticular disease are at 
greater risk of complications and we have demonstrated the 
burden of this at a human level through our case. However, 
many individuals have clinically silent diverticular disease 
which presents both a risk to patients and a challenge to 
cardiologists.
Diverticulosis is often detected during imaging for 
other reasons and there is currently no indication to mon-
itor these individuals further as a result of the finding.12 
Before starting nicorandil therapy, patients do not routinely 
undergo investigations to look for the presence of diver-
ticula. Current methods of identifying diverticular disease 
include CT scanning and colonoscopy, both of which are 
expensive and have risks. The aetiology of diverticular dis-
ease has shifted latterly with advances in genetic studies re-
vealing 48 associated loci.13 Epidemiological studies have 
predicted the heritability of diverticular disease to be up to 
50% with an increased prevalence of diverticula noted in 
monozygotic co- twins compared to dizygotic co- twins.12,14 
Advances in pharmacogenetics have shown that people 
with a high genetic risk of diverticular disease are more 
likely to stop nicorandil therapy early.15 This provides an 
insight to future strategies aimed at tailoring antianginal 
treatment based on individual patient risk of adverse drug 
effects.
The pharmacogenomic advances are an exciting pros-
pect that will hopefully reduce the incidence of future ulcers 
and fistulas in years to come. Today, the focus must remain 
on educating patients prescribed nicorandil and all health-
care professionals to the risk of nicorandil's off- target side 
effects. Nicorandil is prescribed for symptom control of 
angina and shows no long- term benefit to survival. When 
side effects are suspected it is important to stop nicorandil 
therapy promptly to limit patient harm. Discussions with 
cardiology regarding an alternative antianginal should 
not delay cessation of nicorandil.9 A surgical case series 
has shown that stopping nicorandil resulted in improved 
healing of anal ulcers; whereas all surgical interventions 
to treat the ulcers were unsuccessful.16 Additionally, stop-
ping nicorandil was also shown to promote the healing of 
previously non- healing surgical wounds in another surgical 
case series.17
Our case highlights the importance of all healthcare pro-
fessionals performing a thorough medication review when a 
patient presents with new symptoms. For those who prescribe 
nicorandil, it is imperative to consider the high prevalence 
of diverticular disease in the Western world today and to in-
form patients of nicorandil's adverse effects when prescribed. 
Many patients requiring antianginals will have had previous 
abdominal imaging performed; reviewing this information 
and identifying those at risk of side effects can allow for al-
ternative antianginal therapies to be offered.
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